Introduction
Apoptosis is a genetically programmed, morphologically distinct form of cell death that can be triggered by a variety of physiological and pathological stimuli. Apoptosis is characterized by cell rounding, membrane blebbing, cytoskeletal collapse, cytoplasmic condensation and fragmentation, nuclear pyknosis, chromatin condensation/fragmentation, and formation of membrane-bound apoptotic bodies that are rapidly phagocytosed and digested by macrophages or neighboring cells (Kerr et al., 1972; Wyllie et al., 1980; Clarke, 1990) . Physiologic cell death occurs primarily through this evolutionarily conserved form of cell suicide, apoptosis. In multicellular organisms, homeostasis is maintained through a balance between cell proliferation and cell death.
Alterations in apoptosis contribute to the pathogenesis of a number of human diseases including cancer, and also to the therapeutic resistance observed in some human cancer (Thompson, 1995) . Defects in apoptosis underlie both tumorigenesis and drug resistance, and because of these defects chemotherapy often fails (Johnstone et al., 2002) .
The epidermal growth factor receptor (EGFR) pathway has been implicated in the pathogenesis of several human tumors, including those of the brain, breast, lung, head and neck (Rowinsky, 2004) . Overexpression of EGFR is associated with higher invasiveness, higher proliferation, or reduced survival in a variety of cancers, and is being intensively investigated as a target for cancer therapy (Herbst et al., 2004; Rowinsky, 2004) .
Regulation of EGFR signaling is implicated in the control of many cellular functions, whereas its deregulation is often associated with human diseases such as cancer (Ullrich and Schlessinger, 1990; Hunter, 1997) . Defective EGFR downregulation might result in malignant transformation of cells (Di Fiore and Gill, 1999) . Negative regulation of EGFR by lysosomal degradation of EGFR upon ligand binding controls the strength and duration of EGFR signals and is critical to prevent EGFR hyperactivation, commonly associated with tumorigenesis (Hunter, 1997; Di Fiore and Gill, 1999) .
The caspases, a family of cysteine-dependent aspartate-directed proteases, are prominent among the death proteases. Regulation of caspase activation and activity occurs at several different levels (Earnshaw et al., 1999) . In apoptosis, activation of caspases turns off a number of signals and leads to the eventual cell death. Once activated, caspases cleave a variety of intracellular polypeptides, including major structural elements of the cytoplasm and nucleus, components of the DNA repair machinery, and a number of protein kinases (Earnshaw et al., 1999) . EGFR signaling serves as one of the critical survival signals, which may become the target of caspase activation, in order to assure the execution of apoptosis. EGFR was down-regulated in response to apoptosis by a few treatments (Bae et al., 2001; He et al., 2003a; Zhuang et al., 2003) . However, whether EGFR was a direct substrate of caspases in vivo and the mechanism involved remains largely unknown.
In this study, we have investigated the underlying biochemistry and the physiological significance of EGFR downregulation in apoptotic cells. We have demonstrated that EGFR degradation upon caspase activation is neither stimulus-nor cell type-specific. In addition, this process was independent of EGFR internalization. We have mutated the five aspartic acids (D) that may be potential caspase cleavage consensus sequences and identified the caspase cleavage site in the C-terminus region of EGFR. The N-and C-terminus cleavage fragments have been detected. We found that a cleavage-deficient EGFR mutant inhibited cell death.
Results
EGFR downregulation during apoptosis is neither stimulispecific nor cell-type-specific To determine whether other stimuli have a similar effect in addition to tumor necrosis factor-a (TNF-a)/cycloheximide (CHX), photosenstization of rose Bengal, and ultraviolet A (UVA), ultraviolet B (UVB) and ultraviolet C (UVC) (Bae et al., 2001; He et al., 2003a; Zhuang et al., 2003) , we treated HaCaT cells for 6 h with actinomycin D (AD, 10 mM), camptothecin (CA, 2 mM), cycloheximide (CY, 100 mM), etoposide, (EP, 100 mM), paclitaxel (PA, 2 mg/ml), staurosporine (ST, 0.5 mg/ml), doxorubicin hydrochloride (DX, 5 mg/ ml), or puromycin dihydrochloride (PU, 20 mg/ml). All of these treatments caused caspase-3 activation and parallel EGFR downregulation (Figure 1a) . Interestingly, in addition to EGFR, we found that Neu, the second member of the EGFR family, and the plateletderived growth factor receptor (PDGFR) were also degraded ( Figure 1a ). This suggests that EGFR degradation during apoptosis is not stimulus specific.
In order to determine whether EGFR degradation upon caspase activation is cell-type specific, we treated COS-7 (monkey kidney cells), HeLa (cervical cancer cells), A431 cells, and primary mouse keratinocytes with UVA, ST, or UVB. EGFR degradation was detected in all cell lines (Figure 1b) , indicating that EGFR degradation is not cell-type specific.
Although a 160 kDa fragment has been observed in the in vitro reaction between purified EGFR and active caspase-3 (Bae et al., 2001) , no cleavage fragment has been detected in vivo. Using an antibody, which recognizes the N-terminus of EGFR, we detected a 160 kDa fragment in CA-treated HaCaT cells and STtreated HeLa cells but not in control cells (Figure 1c ). These data imply that in vivo EGFR could be a direct substrate of active caspase-3.
EGFR degradation and caspase-3 activation occurred in the same cell population To quantitate the apoptosis, we treated HaCaT cells with CA and determined apoptosis by flow cytometry following staining with Annexin-V/propidium iodide (PI). CA induced B30.5% early apoptotic cells and 33.5% late apoptotic cells at 6 h ( Figure 2a) . The presence of the caspase-3 inhibitor DEVD (20 mM) delayed the progression of early apoptotic cells to late apoptotic cells, that is, loss of membrane integrity, while no effect was seen in total apoptotic cells induced by CA. In contrast, the presence of the pan-caspase inhibitor VAD (20 mM) reduced the total of apoptotic cells (Figure 2a) . Similarly, a longer treatment (15 h) with CA increased late apoptotic cells but not total apoptotic cells, and cells were protected from apoptosis in the presence of VAD but not DEVD (Figure 2b ). The presence of DEVD delayed but did not block DNA fragmentation (Figure 2c ). These data suggest that although activation of caspase-3 by CA is involved in the destruction of membrane integrity, it is not required for phosphatidylserine translocation measured by Annexin-V staining; thus exists caspase-independent apoptosis. ) and incubated for 6 h. Cell lysates were analysed with antibody specific for EGFR. (c) HaCaT cells and HeLa cells were treated with CA (2 mM) and ST (0.5 mg/ml), respectively, for 6 h. Cell lysates were analysed with antibodies specific to the N-terminus region of EGFR (N-EGFR, EGFR LA22).
To determine whether EGFR degradation occurred in the same population, we treated HaCaT cells with camptothecin and fixed and stained the cells with EGFR/active caspase-3 antibody. While only one cell population was seen in the control, an additional cell population with positive active caspase-3 staining and lower EGFR staining was detected after CA treatment (Figure 2d ). The latter population was completely abolished in the presence of DEVD or VAD. These data suggest that EGFR was degraded in cells with caspase-3 activation.
As was the case for UVA-induced EGFR degradation (He et al., 2003a) , the presence of VAD and DEVD blocked EGFR degradation by CA (Figure 2e ). When we separated the attached and floating cells 15 h after CA treatment, EGFR degradation was detected in floating cells but not attached cells (Figure 2f) . In floating cells, it was inhibited but was not completely blocked by VAD. Thus other processes may be involved in the decrease in EGFR levels in dead cells.
EGFR degradation does not require its internalization
We have shown previously that EGFR was internalized upon UVA exposure and translocated to early and late endosomes (He et al., 2003a) . Here we observed EGFR internalization in the same live cells after treatment by using EGFR-GFP in ST-treated COS-7 cells (Figure 3a) . In HaCaT cells, EGFR was internalized after CA treatment (Figure 3b ). When COS-7 cells were transfected with dominant-negative dynamin (K44A), internalization and vesicle pinch-off by ST treatment were blocked (Figure 3c ), indicating that, like EGF, ST-induced EGFR internalization required functional dynamin (Conner and Schmid, 2003) . Cholesterol depletion also blocked EGFR internalization (Figure 3d ), suggesting that the cholesterol content played an important role in the internalization of EGFR induced by CA, similar to ligand-binding-induced EGFR internalization (Rodal et al., 1999; Subtil et al., 1999) .
To determine whether EGFR internalization is required for its degradation as in EGF-induced EGFR degradation (Heldin et al., 1979) , we transfected COS-7 or HeLa cells with dominant-negative dynamin K44A and then treated the cells with UVA or ST. K44A had no effect on EGFR degradation induced by UVA or ST (Figure 3e ). Depletion of cholesterol by treatment with methyl-b-cyclodextrin (MbCD) failed to block EGFR degradation by CA in HaCaT cells (Figure 3f ). These data indicate that EGFR internalization is not required for its downregulation.
Lysosomal translocation of EGFR does not lead to the involvement of lysosome in EGFR degradation
By transfection with EGFR-GFP in HaCaT cells and treatment with CA, we were able to detect EGFR internalization (as indicated in Figure 4a ) in roughly 30% cells (data not shown). EGFR was localized in vesicles close to but not within the Golgi apparatus ( Figure 4a ). Consistent with our previous study (He et al., 2003a) , EGFR was localized in acidic compartments positively stained by lysoTracker after However, when we treated the cells with CA in the absence of VAD, loss of mitochondrial staining by MitoTracker was observed in cells with condensed and fragmented nuclei, indicating that caspase activation led to mitochondria dysfunction (Figure 4c ). When the cells were stained with LysoTracker, cells with the typical apoptotic nuclei showed no lysosomal staining (Figure 4d ), indicating that apoptotic cells failed to maintain their lysosomal pH gradient and acidic environment due to the decline in ATP levels caused by caspase-dependent disruption of mitochondrial function (Ricci et al., 2004) . These data suggest that disruption of lysosomal function in apoptotic cells excluded lysosome involvement in EGFR degradation in contrast to EGF-induced receptor degradation.
AEBSF inhibited EGFR degradation partially
To determine whether other non-caspase proteases were involved, we treated HaCaT cells with CA in the presence of the following protease inhibitors, AEBSF (A, 500 mM, serine proteases), aprotinin (P, 150 nM, serine proteases and esterases), E-64 (E, 1 mM, cysteine proteases), EDTA (D, 0.5 mM, metalloproteases); leupeptin (L, 1 mM, cysteine proteases and trypsin-like proteases), and mixture of the above five inhibitors (M). Of the five inhibitors only AEBSF protected EGFR from degradation after CA treatment (Figure 5a ). The mixture of the five inhibitors had a protective effect equal to AEBSF alone. These data suggest that AEBSF-sensitive serine proteases may be involved in EGFR degradation. In parallel, AEBSF or the mixture also inhibited capase-3 activation partially (Figure 5a ). When the cell were pretreated with cathepsin/papain inhibitor I (C, 20 mM), another metalloprotease inhibitor GM6001 (G, 25 mM), VAD (V, 20 mM), or the combination of two or three of them, VAD predominantly blocked CA-induced EGFR degradation, while cathepsin inhibitor I and metalloprotease inhibitor had no effect (Figure 5b ). These data indicate that neither cathepsin/papain nor metalloproteases are involved in EGFR degradation.
Caspase-3 cleaves EGFR at its consensus sequence at C-terminus Although the C-terminus of EGFR contains five caspase cleavage consensus sequences (DXXD), that is, DEED1006, DMDD1009, DVVD1012, DSID1083, and DNPD1172, the exact cleavage sites both in vitro and in vivo remain unknown. We mutated aspartic acid (D) to alanine (A) at 1006 (site 1), 1009 (site 2), 1012 (site 3), 1083 (site 4), and/or 1172 (site 5) (Figure 6a ). When the membrane fractions of wild-type (WT) or mutant EGFR transfected HEK293 cells were incubated with recombinant active caspase-3 (rCas-3), wild-type EGFR was cleaved by active caspase-3 and a 160-kDa fragment was detected by immunoblotting (Figure 6b ). This is consistent with the in vivo data shown in Figure 1c . Similar results were observed when immunoblotting with V5 antibody, the C-terminus tag of EGFR. D1172A, D1083A, and D1006A failed to prevent the cleavage of EGFR by active caspase-3, indicating that these three consensus sequences are not effective caspase-3 cleavage sites. In contrast, single D1009A or D1012A blocked EGFR cleavage by active caspase-3, suggesting these two aspartic acids are within the caspase-3 cleavage sites. The combinations of two, three, four, or all five sites also confirmed that D1009A and D1012A are required for the cleavage of EGFR by caspase-3.
We took advantage of including the V5 tag at the Cterminus of EGFR and performed the immunoblot with anti-V5 antibody with the film exposed for a longer time. Two cleavage C-terminus fragments were detected for wild-type EGFR at B32 and 10 kDa, whereas only the B32 kDa fragment was detected for D1172A mutants (Figure 6c ). The presence of DEVD, the caspase-3 inhibitor, blocked EGFR cleavage completely (Figure 6d) . However, the anti-EGFR antibody recognizing the C-terminus failed to detect the cleavage fragments at B32 and 10 kDa. These findings suggest that in vitro active caspase-3 cleaves EGFR due to the presence of D1009, D1012, and D1172.
EGFR is a direct substrate of active caspase in vivo We transfected HeLa cells with constructs expressing wild-type EGFR or EGFR with all of the five D to A mutations (54321) without the V5 tag. Wild-type EGFR was downregulated after ST treatment and a 160-kDa fragment was detected (Figure 7a ). The presence of VAD prevented the downregulation of EGFR. In contrast, the EGFR mutant failed to undergo degradation after ST treatment that activated caspases. The mutant 5 was cleaved by ST treatment, while the mutants 532, 5431, and 5421 were not subjected to the cleavage after ST treatment (Figure 7b ). These in vivo data were consistent with those of the in vitro reaction (Figure 6b ), suggesting that in vivo activated caspases cleaved EGFR directly. Similar to wild-type EGFR, however, mutant 54321 was degraded upon EGF (100 ng/ml) treatment and VAD had no effect on EGFR degradation (Figure 7c ), indicating that this mutant retained its downregulation capability by ligand binding.
When HaCaT cells transfected with wild-type EGFR tagged with V5 were treated with CA, a B32 kDa fragment was observed after immunoblotting with V5 (Figure 7b ). However, we were not able to detect the 10 kDa fragment even with overnight exposure.
We also separated cell pellet, blebs, and microparticles by serial centrifugation (Nusbaum et al., 2005) and determined EGFR levels in these fractions. In cells pellets isolated with 500 or 2000 g centrifugation, EGFR was down-regulated by CA treatment and the presence of DEVD or VAD blocked this process (Figure 7c ). In contrast, blebs in the supernatant after 500 g centrifugation, collected by 2000 g centrifugation, contained predominantly the 160-kDa fragment after CA treatment; the presence of DEVD or VAD abolished this fragment and the full-length receptor was detected. In . At 6 h after irradiation, cell lysates were analysed with antibody specific to V5. (e) HaCaT cells were pretreated with or without DEVD or VAD (20 mM) and then treated with camptothecin (CA). Cell pellets, blebs, and microparticles were isolated as described in the Materials and Methods. The lysates were analysed with antibody specific to N-EGFR (LA22). The N-terminus fragment of 160 kDa was indicated.
comparison, a much smaller corresponding signal was detected in microparticles.
Caspase cleavage sites in EGFR is conserved in mammals
When the human EGFR sequence was aligned with those of other mammals, including the mouse, rat, dog, pig, and cow (NCBI database), it turned out that the five caspase cleavage sites are highly conserved (Figure 8b ). In chickens, the functional cleavage sites at DME-DIVD1012 and DNPD1172 (as determined by our in vitro experiments in human cells) were conserved although DEED1006 was replaced with EEED and DSID1083 with ESID.
Blocking EGFR degradation inhibited and delayed cell death Since EGFR plays a crucial role in cell proliferation, differentiation, and transformation, it seemed reasonable to ask whether the cleavage of the receptor by activated caspase during apoptosis may in turn regulate the apoptosis process. To answer this question, we infected HaCaT cells with an adenovirus construct of wild-type EGFR or mutant EGFR with all caspase cleavage sites mutated. EP treatment lead to dosedependent cell death in wild-type-EGFR-nfected HaCaT cells (Figure 9a ). In contrast, while after etoposide treatment for 6 h, infection with mutant EGFR reduced cell death, no difference was seen after 24 h treatment with EP (Figure 9b ). These data indicate that blocking EGFR degradation by EP treatment slightly delayed cell death in the early stage but was unable to rescue cells from death. Similar to EP, CA induced less cell death at 6 h in mutant EGFR-infected cells as compared with wild-type EGFR-infected cells (Figure 9c ). However, 24 h after CA treatment, no difference in cell death was observed (Figure 9d ). Increased expression of wild-type and mutant EGFR was detected when HaCaT cells were infected with the corresponding adenovirus constructs (Figure 9e) . In survived cells, no difference in EGFR levels was observed between control and EP (or CA) treatment, consistent with our above observation that EGFR cleavage was apoptosis dependent.
Discussion
Apoptosis is a key regulatory process that is not only crucial for maintaining tissue homeostasis and preventing cancer but also for achieving an efficient therapeutic outcome in cancer therapy. Caspase activation is a hallmark for apoptosis. The cleavage of a number of substrates by activated caspases disrupts survival pathways and disassembles important architectural components of the cell, contributing to the stereotypic morphological and biochemical changes that characterize apoptotic cell death (Earnshaw et al., 1999) . Here we have shown that EGFR is a direct substrate for active caspase-3-related proteases in vivo and identified the cleavage sites. EGFR downregulation by caspase contributes to the cell death.
The present work demonstrates that EGFR is downregulated in apoptotic cells with caspase activation in response to a variety of apoptotic treatments including chemotherapeutic compounds. It appears that downregulation of EGFR upon executing caspase activation is a generic reaction rather than stimulus or cell typespecific. Similar downregulation by active caspases may also hold true for some other receptor tyrosine kinases (RTKs) such as Neu, another member of the EGFR family and PDGFR (Zhuang et al., 2003; Tulasne et al., 2004) . Those RTKs seem to be the cleavage targets for activated caspases, confirming the execution function of caspases to assure cell death.
Although inhibiting caspase-3 by DEVD failed to rescue cells from apoptosis, EGFR downregulation was blocked. The pan-caspase inhibitor VAD had a similar inhibitory effect. This suggests that caspase-3, not the initiating caspases such as caspase-8 or -9, is responsible for EGFR cleavage. Caspase-7 could also be involved in EGFR downregulation in vivo since it has a similar substrate consensus sequence (Earnshaw et al., 1999; Bae et al., 2001 ). Caspase-3 seems to be responsible for EGFR and MET downregulation (Tulasne et al., 2004) . It may also participate in the downregulation of Neu, in addition to the known role of caspase-8, which has been shown to cleave Neu (Benoit et al., 2004 ). It appears that metalloproteases, cathepsin/palpain, and other cysteine proteases are not involved in EGFR downregulation. The protective effect of AEBSF may be due to its antiapoptotic effect on cells (Kagaya et al., 1997; Park et al., 2000) . However, the possible involvement of AEBSF-sensitive proteases remains an open question.
EGFR is specifically cleaved at DVVD1012 and DNPD1172 at its C-terminus. In comparison, DEED1006 is not subject to caspase-3 cleavage. Caspase-3 may not cleave at DMED1009 either, although EGFR cleavage is blocked by the D1009A mutation while D1006A has no effect. Either D(A) mutation in DVVD1012 blocks EGFR cleavage. The replacement of aspartic acid (D) with alanine (A) at the P4 subsite nearly eliminated the substrate cleavage by either caspase-3 or caspase-7 (Stennicke et al., 2000) , which are two of the caspases responsible for EGFR downregulation (Bae et al., 2001) . Therefore, DVVD1012 is most likely the major target site of active caspase-3. Although the cleavage fragment at DNPD1172 was detected in vitro, the efficiency is not equal: the B10 kDa band is much weaker than the B32 kDa one. The D1172A mutant did prevent the appearance of the 10 kDa band but neither blocked the cleavage of EGFR nor enhanced the 32 kDa band, indicating that the cleavage of caspase-3 at DNPD1172 is much less efficient than at DVVD1012 (Figure 8a ). The presence of alanine following D1012 may favor DVVD1012 for caspase cleavage more than other sites with consensus sequences (Stennicke et al., 2000) .
Although EGFR internalization occurs in a subpopulation of cells upon apoptosis-inducing treatment with the underlying mechanisms unclear, the downregulation of the receptor is independent of this process. Inhibition of EGFR internalization fails to prevent its cleavage by activated caspase. The predominant presence of the N-terminus cleavage fragment in the blebs confirms that the receptors remaining at the plasma membrane during apoptosis are subject to cleavage at its C-terminus by the activation of caspases, similar to those internalized. The full-length receptor was not detected in the blebs, possibly because membrane blebbing during apoptosis may be caspase dependent (Coleman et al., 2001) . However, the full-length receptor was observed in the blebs when caspase-3 or all of the caspases were inhibited. This suggests that caspaseindependent cell blebbing mechanisms exist in the cell and allows this process to proceed in the absence of caspase activity. The loss of EGFR in floating cells in the presence of pan-caspase inhibitor might be due to the increased full-length EGFR level in the blebs. This evidence confirms that EGFR downregulation in apoptotic cells is caspase dependent, independent of the location of the receptor, that is, at the plasma membrane or inside the cells (at the endocytic compartments). EGFR downregulation during apoptosis plays an important role in inhibiting apoptosis. The cleavage of EGFR at DVVD1012 removed the signaling sequence at the C-terminus of EGFR, such as Y1045 and Y1068, the Cbl and Grb2 docking sites. The activation of caspase-3 indicates that the cells are committed to apoptosis and the executing scissor cleaves a variety of substrates to allow the cells to die. Although EGFR is a key signaling protein in cells, the disruption of other key survival proteins may be sufficient to allow the cells to die eventually. Downregulation of EGFR during the early time period delayed the apoptosis progression but was not able to rescue the cells from death. This effect in timing could be significant in vivo when cells are in complex circumstances in the presence of multiple enhanced survival signaling pathways. The possible interaction of EGFR downregulation with other survival pathways during apoptosis remains to be understood.
In conclusion, we have demonstrated EGFR downregulation by active caspases during apoptosis in different cell types treated with different stimuli. Active caspase-3 cleaves EGFR at DVVD1012 and to a lesser extent DNPD1172. EGFR downregulation by apoptosis-inducing treatment is independent of its internalization. A cleavage-deficient EGFR mutant protected cells from death. These findings demonstrate that EGFR interacts directly with caspase, which plays an important role during apoptosis.
Materials and methods
Plasmids/adenovirus V5-tagged wild-type EGFR was generated by PCR amplification of pCDNA3-EGFR, a kind gift from Sally Parsons (University of Virginia). The PCR product was subcloned into pCDNA3.1-V5/His (Invitrogen). All the mutations were done using QuikChange Site-Directed Mutagenesis kit (Stratagene). The same method was used to recover stop codon to remove the V5/His tag in wild-type and mutant EGFR. Wild-type and mutated EGFR in Adenovirus was prepared using the AdEasy Adenovirus vector system (Stratagene). Dominantnegative dynamin (K44A) was kindly provided by Mariel Birnbaumer (NIEHS/NIH). EGFR-GFP was a kind gift from Philippe Bastiaens (EMBL-Heidelberg, Germany). Golgi-CFP was generously provided by Becky Boyles (NIEHS/NIH).
Cell culture and transfection/infection
The human HaCaT keratinocyte (obtained from Professor N Fusenig, German Cancer Research Center, Heidelberg, Germany), COS-7, HeLa, and A431 (ATCC) were maintained in monolayer culture in 95% air/5% CO 2 at 371C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 31 mg/ml penicillin, and 50 mg/ml streptomycin. Primary mouse keratinocytes were extracted and cultured as described previously (Akunda et al., 2004) . Cells to be examined by Western blotting were seeded at 4-8 Â 10 5 cells per plate (60 mm) and transfected/infected the next day. Transfections were performed with Fugene (Roche, Indianapolis, IN, USA). For double transfection, 1 mg of dominant dynamin (K44A) and 0.1 mg of EGFR-GFP (a ratio of 10:1) were used to allow cotransfection of EGFR-GFP with K44A in the cells. Infection was performed at a multiplicity of infection (MOI) of 50.
Flow cytometry determination of EGFR levels and caspase-3 activation Briefly, HaCaT cells were treated and fixed with 4% formaldehyde. After permealization with 90% methanol, cells were double stained with anti-EGFR-FITC (Santa Cruz) and antiactive caspase-3-PE (BD Biosciences) antibodies. The EGFR levels and activation of caspase-3 in cells were determined by flow cytometry.
In vitro EGFR cleavage of EGFR by recombinant caspase-3 Wild-type and mutant EGFR were transfected into 293 cells. At 48 h after transfection, cells were harvested and the membrane fraction was extracted and dissolved as described previously (He et al., 2004) . The reactions were initiated by the addition of recombinant active caspase-3 (BD Biosciences) and incubated for 1 h at 371C in cleavage assay buffer (20 mM HEPES, pH 7.4, 100 mM KCl, 3 mM CaCl 2 , and 1 mM dithiothreitol) (Bae et al., 2001) .
Isolation of blebs and microparticles
After the usual centrifugation for 10 min at 500 g, cell pellets were collected (pellet-500 g). The supernatant was centrifuged for 20 min at 2000 g and the pellet was taken as blebs. Further ultracentrifugation of the supernatant, for 1 h at 100 000 g allowed recovery of the microparticles (Nusbaum et al., 2005) The pellet-2000 g samples were obtained as the pellets from direct centrifugation of cells for 20 min at 2000 g.
Determination of apoptosis
Apoptosis was determined by Annexin-V/propidium iodide (PI) staining followed by flow cytometry, as described previously (He et al., 2003b) . DNA fragmentation was determined as described previously (He et al., 2003a) .
Determination of cell viability
At 6 or 24 h after etoposide treatment, the cell viability was measured using the MTS assay (CellTiter 96 Aqueous Proliferation Assay Promega) and monitored at 492 nm using a Spectrafluor plate reader.
